As Director of Translational Research at Entact Bio, Dr Chipumuro brings more than 10 years of oncology drug discovery experience using various drug modalities. Most recently, Dr Chipumuro was Director and Head of Oncology at Faze Medicines, where he was responsible for building a team and providing scientific leadership to advance novel therapies targeting biomolecular condensates. Previously, Dr Chipumuro was at AstraZeneca where he led a program targeting epi-transcriptomics utilizing targeted protein degradation. Prior to this, he joined KSQ Therapeutics as one of the early employees to build a proprietary CRISPR-omics platform and worked on several DNA Damage and Repair programs. He began his industry career at Dicerna Pharmaceuticals where he helped advance the company’s siRNA platform.
Dr Chipumuro completed his Hon. BSc & MSc at University of Zimbabwe and PhD in Molecular Biology from the University of Virginia. He moved to Boston and completed a Post-Doc in Rani George’s lab at Dana Farber Cancer Institute.